For example, various studies have shown that targeting pathways involved in melanoma tumor growth and survival including BRAF and MAPK pathways with specific inhibitors such as vemurafenib and trametinib, respectively, contribute to enhanced overall survival of metastatic melanoma patients [143,144]. This evidence concerns the gene BRAF and metastatic melanoma.